The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hansen Carl L. G. since 2021.
This trader's CIK number is 1834412.
At the time of last reporting, Hansen Carl L. G. was the Chief Executive Officer of Abcellera Biologics Inc.. (stock ticker symbol ABCL).
Also see all insider trading activities at Abcellera Biologics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | ABCL | 0 | $0 | 0 | $0 | 280,625 | $757,685 |
| 2023 | ABCL | 0 | $0 | 0 | $0 | 224,500 | $606,148 |
| 2022 | ABCL | 0 | $0 | 0 | $0 | 224,500 | $606,148 |
| 2021 | ABCL | 0 | $0 | 6,000,000 | $148,590,000 | 224,500 | $3,374,235 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-25 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2024-09-20 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2024-05-31 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2024-05-31 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2024-02-26 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2023-11-23 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2023-08-24 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2023-05-26 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2023-02-22 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2022-11-18 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2022-08-18 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2022-05-18 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2022-02-22 | ABCL | Option Ex | 56,125 | 2.70 | 151,537 |
| 2021-11-18 | ABCL | Option Ex | 224,500 | 15.03 | 3,374,235 |
| 2021-06-09 | ABCL | Sale | 6,000,000 | 24.77 | 148,590,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hansen Carl L. G. (Chief Executive Officer of Abcellera Biologics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.